Actinogen pivotal Alzheimer’s disease trial demonstrates clinical benefit in older patients with mild to moderate disease, favorable safety profile and trends towards benefit in the overall population
In participants over 75 years, significant improvement in rates of stable, non-progressive disease for Xanamem of 40% vs. 22% for placebo (p=0.02), associated with a 30% slowing of disease progression SYDNEY, Nov.